Dyne Therapeutics, Inc.
DYN
$9.57
-$0.48-4.78%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -367.13M | -317.42M | -294.51M | -257.60M | -257.40M |
| Total Depreciation and Amortization | 1.79M | 1.67M | 1.62M | 1.62M | 1.65M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 35.88M | 42.87M | 38.73M | 35.53M | 34.57M |
| Change in Net Operating Assets | 9.74M | -19.49M | 11.12M | 1.44M | 1.40M |
| Cash from Operations | -319.73M | -292.37M | -243.04M | -219.01M | -219.79M |
| Capital Expenditure | -3.17M | -2.38M | -1.38M | -1.30M | -690.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -19.62M | -201.70M | -160.49M | -128.35M | -122.90M |
| Cash from Investing | -22.78M | -204.08M | -161.87M | -129.65M | -123.59M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 542.75M | 809.90M | 806.41M | 788.85M | 433.90M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 542.75M | 809.90M | 806.41M | 788.85M | 433.90M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 200.24M | 313.45M | 401.50M | 440.19M | 90.52M |